TNFSF11 and neoplasm: More importantly, [64Cu]Cu-NOTA-denos-Fab showed a statistically significant increase in tumor uptake compared with [64Cu]Cu-NOTA-denosumab at 1 h (p = 0.0002) and at 5 h p.i. (p = 0.0452) in RANKL-ME-180 xenografts.